Monosomal karyotype in MDS: Explaining the poor prognosis

Leukemia

Volumn 27, Issue 10, 2013, Pages 1988-1995

  Schanz, J ^a   Tuchler H ^b   Sole F ^c   Mallo, M ^c   Luno E ^d   Cervera, J ^e   Grau, J ^f   Hildebrandt, B ^g   Slovak, M L ^h   Ohyashiki, K ⁱ   Steidl, C ^j   Fonatsch, C ^k   Pfeilstocker M ^l   Nosslinger T ^l   Valent, P ^k   Giagounidis, A ^m   Aul, C ⁿ   Lubbert M ^o   Stauder, R ^p   Krieger, O ^q   Le Beau, M M ^r   Bennett, J M ^s   Greenberg, P ^t   Germing, U ^g   Haase, D ^a   more..

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Institute for Leukemia Research   (Austria)

^c JOSEP CARRERAS LEUKAEMIA RESEARCH INSTITUTE IJC   (Spain)

^d University Hospital of Asturias   (Spain)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^g HEINRICH HEINE UNIVERSITY   (Germany)

^h SONORA QUEST LABORATORIES   (United States)

ⁱ TOKYO MEDICAL UNIVERSITY   (Japan)

^j BRITISH COLUMBIA CANCER AGENCY   (Canada)

^k MEDICAL UNIVERSITY OF VIENNA   (Austria)

^l HANUSCH HOSPITAL   (Austria)

^m MARIEN HOSPITAL DÜSSELDORF   (Germany)

ⁿ Johannes Hospital   (Germany)

^o UNIVERSITY OF FREIBURG   (Germany)

^p INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^q ELISABETHINEN HOSPITAL   (Austria)

^r UNIVERSITY OF CHICAGO   (United States)

^s UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^t STANFORD CANCER INSTITUTE   (United States)

more..

Author keywords

cytogenetics; MDS; monosomal karyotype; prognosis

Indexed keywords

EID: 84885641233     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.187     Document Type: Article

References (35)

1. Garcia-Manero G. Myelodysplastic syndromes: update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87: 692-701.
2. Haase D, Feuring-Buske M, Schäfer C, Schoch C, Troff C, Gahn B et al. Cytogenetic analysis of CD34 subpopulations in AML and MDS characterized by the expression of CD38 and CD117. Leukemia 1997; 11: 674-679.
3. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
4. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454-2465.
5. Malcovati L, Germing U, Kuendgen A, Porta Della MG, Pascutto C, Invernizzi R et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25: 3503-3510.
6. Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2007; 22: 538-543.
7. Shaffer LG, Slovak ML, Campbell LJ (eds). An International System for Human Cytogenetic Nomenclature (2009): Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Karger: Switzerland, 2009.
8. Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007; 110: 4385-4395.
9. Schanz J, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Tuechler H et al. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol 2011; 29: 1963-1970.
10. Breems DA, van Putten WLJ, De Greef GE, Van Zelderen-Bhola SL, Gerssen-Schoorl KBJ, Mellink CHM et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008; 26: 4791-4797.
11. Oran B, Dolan M, Cao Q, Brunstein C, Warlick E, Weisdorf D. Monosomal karyotype provides better prognostic prediction after allogeneic stem cell transplantation in patients with acute myelogenous leukemia. Biol Blood Marrow Transplant 2011; 17: 356-364.
12. Fang M, Storer B, Estey E, Othus M, Zhang L, Sandmaier BM et al. Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation. Blood 2011; 118: 1490-1494.
13. Ahn HK, Jang JH, Kim K, Kim H-J, Kim S-H, Jung CW et al. Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome and associates with high functional multidrug resistance activity. Am J Hematol 2012; 87: 37-41.
14. Kayser S, Zucknick M, Döhner K, Krauter J, Köhne C-H, Horst HA et al. Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. Blood 2012; 119: 551-558.
15. Yanada M, Kurosawa S, Yamaguchi T, Yamashita T, Moriuchi Y, Ago H et al. Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission. Haematologica 2012; 97: 915-918.
16. Wudhikarn K, Rheeden R, Leopold C, Rattanaumpawan P, Gingrich R, Silverman MM. Outcome of allogeneic stem cell transplantation in myelodysplastic syndrome patients: prognostic implication of monosomal karyotype. Eur J Haematol 2012; 89: 294-301.
17. Deeg HJ, Scott BL, Fang M, Shulman HM, Gyurkocza B, Myerson D et al. Five-group cytogenetic risk classification, monosomal karyotype and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood 2012; 120: 1398-1408.
18. Van Gelder M, de Wreede LC, Schetelig J, van Biezen A, Volin L, Maertens J et al. Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia. Leukemia 2013; 27: 879-888.
19. Gaillard J-B, Chiesa J, Reboul D, Arnaud A, Brun S, Donadio D et al. Monosomal karyotype routinely defines a poor prognosis subgroup in acute myeloid leukemia and is frequently associated with TP53 deletion. Leuk Lymphoma 2012; 53: 336-337.
20. Rü cker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 2012; 119: 2114-2121.
21. Haferlach C, Alpermann T, Schnittger S, Kern W, Chromik J, Schmid C et al. Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype. Blood 2012; 119: 2122-2125.
22. Patnaik MM, Hanson CA, Hodnefield JM, Knudson R, Van Dyke DL, Tefferi A. Monosomal karyotype in myelodysplastic syndromes, with or without monosomy
23. or 5, is prognostically worse than an otherwise complex karyotype. Leukemia 2011; 25: 266-270.
24. Belli CB, Bengió R, Aranguren PN, Sakamoto F, Flores MG, Watman N et al. Partial and total monosomal karyotypes in myelodysplastic syndromes: comparative prognostic relevance among 421 patients. Am J Hematol 2011; 86: 540-545.
25. Itzykson R, Thépot S, Eclache V, Quesnel B, Dreyfus F, Beyne-Rauzy O et al. Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine. Leukemia 2011; 25: 1207-1209.
26. Valcá rcel D, Adema V, Solé F, Ortega M, Nomdedeu B, Sanz G et al. Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome. J Clin Oncol 2013; 31: 916-922.
27. Schanz J, Tü chler H, Solé F, Mallo M, Luno E, Cervera J et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012; 30: 820-829.
28. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
29. Brunning RD et al. Myelodysplastic syndromes/neoplasms. In: Swerdlow et al. (eds). WHO Classification of Tumors of Hematopoietic and Lymphoid Tissue. IARC Press: Lyon, 2008.
30. Chun K, Hagemeijer A, Iqbal A, Slovak ML. Implementation of standardized international karyotype scoring practices is needed to provide uniform and systematic evaluation for patients with myelodysplastic syndrome using IPSS criteria: an International Working Group on MDS Cytogenetics Study. Leuk Res 2010; 34: 160-165.
31. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass 1958; 53: 457-481.
32. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976; 34: 585-612.
33. Solé F, Luno E, Sanzo C, Espinet B, Sanz G, Cervera J et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 2005; 90: 1168-1178.
34. Herry A, Douet-Guilbert N, Morel F, Le Bris M-J, De Braekeleer M. Redefining monosomy 5 by molecular cytogenetics in 23 patients with MDS/AML. Eur J Haematol 2007; 78: 457-467.
35. Galván AB, Mallo M, Arenillas L, Salido M, Espinet B, Pedro C et al. Does monosomy really exist in myelodysplastic syndromes and acute myeloid leukemia? Leuk Res 2010; 34: 1242-1245.